Sponsor-Investigators

Hope Rugo

TBCRC047

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Status

Open to Accrual

Cancer Types

Breast

Locations

Alabama, California, Dana-Farber Cancer Institute, Duke Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, Illinois, Maryland, Massachusetts, Mayo Clinic, Minnesota, North Carolina, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Tennessee, The University of Chicago Medicine Comprehensive Cancer Center, UC San Francisco, University of Alabama at Birmingham Comprehensive Cancer Center, University of North Carolina Lineberger Comprehensive Cancer Center, Vanderbilt-Ingram Cancer Center, Washington, D.C.

TBCRC035

Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II study with Pharmacodynamics Markers (TBCRC035)

Status

Closed

Cancer Types

Breast

Locations

TBCRC044

A Randomized Phase II Study of Pembrolizumab, an Anti-PD (Programmed Cell Death)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

Status

Closed

Cancer Types

Breast

Locations